ATE344279T1 - Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors - Google Patents

Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors

Info

Publication number
ATE344279T1
ATE344279T1 AT96945800T AT96945800T ATE344279T1 AT E344279 T1 ATE344279 T1 AT E344279T1 AT 96945800 T AT96945800 T AT 96945800T AT 96945800 T AT96945800 T AT 96945800T AT E344279 T1 ATE344279 T1 AT E344279T1
Authority
AT
Austria
Prior art keywords
ligand
crystals
binding domain
hormone receptor
thyroid hormone
Prior art date
Application number
AT96945800T
Other languages
English (en)
Inventor
Thomas S Scanlan
John D Baxter
Robert J Fletterick
Richard L Wagner
Peter J Kushner
James L Apriletti
Brian L West
Andrew K Shiau
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE344279T1 publication Critical patent/ATE344279T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
AT96945800T 1995-12-13 1996-12-13 Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors ATE344279T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US854095P 1995-12-13 1995-12-13
US854395P 1995-12-13 1995-12-13
US860695P 1995-12-14 1995-12-14

Publications (1)

Publication Number Publication Date
ATE344279T1 true ATE344279T1 (de) 2006-11-15

Family

ID=27358633

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96945800T ATE344279T1 (de) 1995-12-13 1996-12-13 Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors

Country Status (8)

Country Link
US (1) US6236946B1 (de)
EP (1) EP0873361B1 (de)
JP (1) JP2000502086A (de)
AT (1) ATE344279T1 (de)
AU (1) AU717743B2 (de)
CA (1) CA2240024A1 (de)
DE (1) DE69636677D1 (de)
WO (1) WO1997021993A2 (de)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021993A2 (en) 1995-12-13 1997-06-19 The Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
US6266622B1 (en) * 1995-12-13 2001-07-24 Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
US6054485A (en) 1996-08-20 2000-04-25 Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
KR20010042373A (ko) * 1998-03-30 2001-05-25 린다 에스. 스티븐슨 핵 수용체 활성을 조절하는 방법 및 화합물
US6965850B2 (en) * 1998-03-30 2005-11-15 The Regents Of The University Of California Methods for modulating nuclear receptor coactivator binding
AU2818200A (en) * 1999-03-01 2000-09-21 Karo Bio Ab Homology models of the glucocorticoid receptor
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
US6516294B1 (en) 1999-07-01 2003-02-04 The Regents Of The University Of California Nuclear receptor for 1α,25-dihydroxyvitamin D3 useful for selection of vitamin D3 ligands and a method therefor
JP2003511467A (ja) 1999-10-14 2003-03-25 ブリストル−マイヤーズ スクイブ カンパニー アンドロゲンレセプターリガンド結合ドメインの結晶構造
US6627660B1 (en) * 1999-11-16 2003-09-30 New River Pharmaceuticals Inc. Stabilized thyroxine compounds
GB0005689D0 (en) * 2000-03-09 2000-05-03 Schering Ag Crystal
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US20020045578A1 (en) * 2000-05-22 2002-04-18 Sukits Steven F. Solution structure of TNFR-1 DD and uses thereof
US6395784B1 (en) * 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
EP1299094A2 (de) * 2000-06-28 2003-04-09 Bristol-Myers Squibb Company Selektive androgenrezeptormodulatoren und methoden zu deren identifizierung, entwurf und verwendung
ATE318272T1 (de) 2001-04-11 2006-03-15 Bristol Myers Squibb Co Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
KR20040054729A (ko) 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
EP1443919A4 (de) 2001-11-16 2006-03-22 Bristol Myers Squibb Co Doppelte hemmer des adipozyten-fettsäure-bindungsproteins und des keratinozyten-fettsäure-bindungsproteins
US20030162758A1 (en) * 2001-12-07 2003-08-28 Schwartz Daniel M. Treatment for age-related macular degeneration (AMD)
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
AU2003251969A1 (en) * 2002-07-18 2004-02-09 Bristol-Myers Squibb Company Compositions and methods involving nuclear hormone receptor site ii
ES2344057T3 (es) 2002-10-23 2010-08-17 Bristol-Myers Squibb Company Inhibidores de la dipeptidil peptidasa iv basados en nitrilos de glicina.
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
EP1567487A4 (de) 2002-11-15 2005-11-16 Bristol Myers Squibb Co Offenkettige, mit prolylharnstoff verwandtemodulatoren der androgenrezeptorfunktion
US7302347B2 (en) * 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
AU2003300852A1 (en) * 2002-12-10 2004-06-30 The Regents Of The University Of California A method for creating specific, high affinity nuclear receptor pharmaceuticals
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2005047297A1 (en) 2003-11-12 2005-05-26 Phenomix Corporation Heterocyclic boronic acid compounds
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
US7786163B2 (en) 2004-07-12 2010-08-31 Forest Laboratories Holdings Limited (BM) Constrained cyano compounds
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7220859B2 (en) 2005-01-12 2007-05-22 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076597A1 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7314882B2 (en) 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
US7238702B2 (en) 2005-02-10 2007-07-03 Bristol-Myers Squibb Company Dihydroquinazolinones as 5HT modulators
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
MX2007014501A (es) * 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos novedosos que contienen acido fosfinico.
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US20060292194A1 (en) * 2005-06-24 2006-12-28 Thomas Lavin Treatment for burns and adipose deposits using thyroid hormone compound in a human
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
EP1943215A2 (de) 2005-10-31 2008-07-16 Brystol-Myers Squibb Company Inhibitoren von dipeptidylpeptidase iv auf pyrrolidinyl-beta-aminoamidbasis und verfahren
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
KR101410453B1 (ko) 2006-08-02 2014-06-27 싸이토키네틱스, 인코포레이티드 소정의 화학 물질, 조성물 및 방법
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
EP2099767A1 (de) 2006-11-01 2009-09-16 Brystol-Myers Squibb Company Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-b-aktivität und deren verwendung
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
CN101687873A (zh) 2007-04-17 2010-03-31 百时美施贵宝公司 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
JP2010534722A (ja) 2007-07-27 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー 新規グルコキナーゼ活性化薬およびその使用方法
BRPI0817211A2 (pt) 2007-09-20 2017-05-16 Irm Llc composto composições como moduladores da atividade de gpr119
EP2209780B1 (de) 2007-11-01 2014-01-01 Bristol-Myers Squibb Company Als modulatoren des glucocorticoidrezeptors ap-1 und/oder der nf-kappa-b-aktivität geeignete nicht steroidale verbindungen und anwendung davon
US8187821B2 (en) * 2008-05-08 2012-05-29 University Of Utah Research Foundation Compositions and methods for the modulation of PGRMC1
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
EP3239170B1 (de) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
EP3241839B1 (de) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
WO2010111665A1 (en) 2009-03-27 2010-09-30 Bristol-Myers Squibb Company Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
CN102459185B (zh) 2009-04-20 2015-06-03 田边三菱制药株式会社 新型甲状腺激素β受体激动剂
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
KR20120092629A (ko) 2009-10-09 2012-08-21 아이알엠 엘엘씨 Ｇｐｒ119 활성의 조절제로서의 화합물 및 조성물
EP2498757A1 (de) 2009-11-13 2012-09-19 Bristol-Myers Squibb Company Metformin-formulierungen mit verringerter masse
CA2780941C (en) 2009-11-13 2018-06-12 Bristol-Myers Squibb Company Immediate release tablet formulations
HUE040486T2 (hu) 2009-11-13 2019-03-28 Astrazeneca Ab Kétrétegû tabletta készítmények
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
US8592396B2 (en) 2010-04-14 2013-11-26 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
EP2892897A1 (de) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolon- oder pyrrolidinon-antagonisten des melaninkonzentrierenden hormonrezeptor-1
US9586900B2 (en) 2012-09-05 2017-03-07 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
NZ707859A (en) 2012-11-20 2019-03-29 Lexicon Pharmaceuticals Inc Inhibitors of sodium glucose cotransporter 1
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP4140497A1 (de) 2013-04-08 2023-03-01 President and Fellows of Harvard College Zusammensetzungen zum verjüngen von stammzellen der skelettmuskulatur
JP2016517883A (ja) 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CN103644180B (zh) * 2013-12-04 2015-12-30 苏州凯欧机械科技有限公司 一种卷膜机支架连接管
FR3023177B1 (fr) 2014-07-04 2016-08-12 Centre Nat De La Rech Scient (C N R S) Procede de preparation de co-cristaux par evaporation flash
EP3442997A2 (de) 2016-04-15 2019-02-20 Indiana University Research & Technology Corporation Fgf21-c-endpeptid-optimierung
KR20190104524A (ko) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
KR102600115B1 (ko) 2017-06-05 2023-11-09 바이킹 테라퓨틱스 인코포레이티드 섬유증 치료를 위한 조성물
JP7360583B2 (ja) 2017-09-14 2023-10-13 国立研究開発法人理化学研究所 網膜組織の製造方法
EP3768690A4 (de) 2018-03-22 2021-11-24 Viking Therapeutics, Inc. Kristalline formen und verfahren zur herstellung kristalliner formen einer verbindung
BR112021000139A2 (pt) 2018-07-19 2021-04-06 Astrazeneca Ab Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
BR112021004839A2 (pt) 2018-09-26 2021-06-08 Lexicon Pharmaceuticals, Inc. formas cristalinas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropan-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-triidróxi-6-(metiltio)tetraidro-2h-piran-2-il)benzil)fenil)butanamida e métodos de sua síntese
CN113423684A (zh) 2018-12-12 2021-09-21 速通医疗公司 新型拟甲状腺素药
CA3130371A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
CN113557311A (zh) 2019-03-13 2021-10-26 大日本住友制药株式会社 移植用神经视网膜的品质评价方法及移植用神经视网膜片
MX2021015468A (es) 2019-06-27 2022-01-24 Cytokinetics Inc Polimorfos de 1-(2-((((trans)-3-fluoro-1-(3-fluoropiridin-2-il)cic lobutil)metil)amino)pirimidin-5-il)-1h-pirrol-3-carboxamida.
CN116194079A (zh) 2020-09-11 2023-05-30 住友制药株式会社 用于移植用组织的介质
US20230313133A1 (en) 2020-09-11 2023-10-05 Riken Complex Containing Neural Retina-Containing Cell Aggregates and Matrix, and Method for Manufacturing Same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8501372D0 (en) 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5061798A (en) 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
US4741897A (en) 1986-07-08 1988-05-03 Baxter Travenol Thyroxine analogs and reagents for thyroid hormone assays
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5171671A (en) 1987-12-02 1992-12-15 The Salk Institute For Biological Studies Retinoic acid receptor composition
US5438126A (en) 1989-09-11 1995-08-01 Arch Development Corporation Human thyroid hormone receptor DNA
US5116828A (en) 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5403925A (en) 1989-12-13 1995-04-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleic acids encoding mammalian H-2RIIBP or RXR.sub.β and uses thereof
US5284999A (en) 1990-04-05 1994-02-08 Brigham And Women's Hospital DNA encoding a pituitary-specific thyroid hormone receptor
US5322933A (en) 1992-05-07 1994-06-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Crystal structure of TGF-β-2
US5466861A (en) 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
WO1997021993A2 (en) 1995-12-13 1997-06-19 The Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
US6054485A (en) 1996-08-20 2000-04-25 Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs

Also Published As

Publication number Publication date
EP0873361A2 (de) 1998-10-28
CA2240024A1 (en) 1997-06-19
DE69636677D1 (de) 2006-12-14
WO1997021993A2 (en) 1997-06-19
WO1997021993A3 (en) 1997-07-24
AU1821697A (en) 1997-07-03
AU717743B2 (en) 2000-03-30
US6236946B1 (en) 2001-05-22
EP0873361A4 (de) 2002-10-23
JP2000502086A (ja) 2000-02-22
EP0873361B1 (de) 2006-11-02

Similar Documents

Publication Publication Date Title
ATE344279T1 (de) Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors
WO1999026966A3 (en) Nuclear receptor ligands and ligand binding domains
CA2094380A1 (en) Radiolabelling
ATE196548T1 (de) Auswählen von agonisten und antagonisten von liganden
DK0573545T3 (da) Monoklonale antistoffer mod receptor-inducerede bindingssteder
DK0708922T3 (da) Identificering af ligander ved selektiv amplifikation af celler transfekteret med receptorer
HK1017379A1 (en) Modified tie-2-receptor ligands
AU2352997A (en) Novel fibronectin receptors
DE69127791D1 (de) Diazabicyclononyl-Derivate als 5-HT3 Rezeptor Antagonisten
BE879380A (fr) Porte-outil a systeme de blocage au moyen d'une cale
DE69819903D1 (de) Bizyklische verbindungen als liganden der 5-ht1 rezeptoren
DE69231274T2 (de) Hyperkinetische bewegungsstörung modulierender opiatrezeptor-antagonist
IT9019242A0 (it) Composizione ibrida di combustibile liquido in microemulsione acquosa
FI873410A0 (fi) Kahden uuden hybridooman tuottamia apolipoproteiini-B-spesifisiä monoklonaalisia vasta-aineita
ES2091513T3 (es) Procedimiento para la preparacion de indanonas sustituidas y su utilizacion.
MX9603199A (es) Antagonistas de receptores a endotelina.
DK0684835T3 (da) Ligandantagonister til behandling af brystcancer
NO831100L (no) Substituerte 3,4-diamino-1,2,5-tiadiazoler med histamin h2-reseptorantagonistvirkning
DK426584D0 (da) Herbicide midler indeholdende fotosyntesehaemmende herbicider i kombination med 1,4-disubstituerede pyrazolderivater
DE69117741D1 (de) Neue vorangeordnete sechszähnige liganden verwendbar in röntgenologischen bildformenden wirkstoffen
FR2550521B1 (fr) Selle d'equitation
Sasanow The elusive multiphase metering prize
Jeffcoat et al. Water Resources Activities in Alabama, 1990-1991
NO843726L (no) 2,5-disubstituerte-4(3h)-pyrimidoner med histamin h2-reseptor antagonistvirkning
FR2665506B1 (fr) Dispositif de suspension d'une canalisation a un element fixe d'une construction.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties